[1] CELLI B, FABBRI L, CRINER G, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision[J]. Am J Respir Crit Care Med, 2022, 206(11): 1317-1325. DOI: 10.1164/rccm.202204-0671PP. [2] 支气管扩张症专家共识撰写协作组,中华医学会呼吸病学分会感染学组.中国成人支气管扩张症诊断与治疗专家共识[J].中华结核和呼吸杂志, 2021, 44(4): 311-321. DOI: 10.3760/cma.j.cn112147-20200617-00717. [3] SEVER Z K, BIRCAN H A, SIRIN F B, et al. Serum biomarkers in patients with stable and exacerbated COPD-bronchiectasis overlap syndrome[J]. Clin Respir J, 2020, 14(11): 1032-1039. DOI: 10.1111/crj.13238. [4] VOGELMEIER C F, CRINER G J, MARTINEZ F J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary[J]. Am J Respir Crit Care Med, 2017, 195(5): 557-582. DOI: 10.1164/rccm.201701-0218pp. [5] SEIFER F D, HANSEN G, WEYCKER D. Health-care utilization and expenditures among patients with comorbid bronchiectasis and chronic obstructive pulmonary disease in US clinical practice[J]. Chron Respir Dis, 2019, 16: 1479973119839961. DOI: 10.1177/1479973119839961. [6] 戴中上,钟严俊,陈燕.慢性阻塞性肺疾病合并支气管扩张症的研究进展[J].结核与肺部疾病杂志,2023,4(6):499-505.DOI: 10.19983/j.issn.2096-8493.20230093. [7] 何婷,贺莹,杨媛,等.慢性阻塞性肺疾病合并支气管扩张治疗的研究进展[J].中国临床研究, 2021, 34(8): 1128-1132. DOI: 10.13429/j.cnki.cjcr.2021.08.030. [8] 崔立静,张树倩,王亮,等.双长效支气管扩张剂治疗支气管扩张症合并慢性阻塞性肺疾病的临床效果及肺功能改善效果研究[J].中国医药,2024,19(1):30-34. [9] 薛强,陈俊文,李平.慢性阻塞性肺病合并支气管扩张症发生机制[J].临床肺科杂志, 2022, 27(8): 1248-1251. DOI: 10.3969/j.issn.1009-6663.2022.08.024. [10] BARNES P J. COPD 2020: new directions needed[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 319(5): L884-L886. DOI: 10.1152/ajplung.00473.2020. [11] 蔡仁萍,潘倩倩,时海洋,等.支气管扩张症合并慢性阻塞性肺病的早期诊治研究[J].中国医师进修杂志, 2018, 41(11): 1025-1029. DOI: 10.3760/cma.j.issn.1673-4904.2018.11.016. [12] JIN J, LI S, YU W, LIU X, et al. Emphysema and bronchiectasis in COPD patients with previous pulmonary tuberculosis: computed tomography features and clinical implications[J]. Int J Chron Obstruct Pulmon Dis, 2018, 13: 375-384. DOI: 10.2147/COPD.S152447. [13] STRANGE C. Alpha-1 antitrypsin deficiency associated COPD[J]. Clin Chest Med, 2020, 41(3): 339-345. DOI: 10.1016/j.ccm.2020.05.003. [14] 胡月颖,车春莉.大气细颗粒物长期暴露对慢性阻塞性肺疾病发病机制的研究进展[J].临床肺科杂志, 2021, 26(10): 1604-1608. DOI: 10.3969/j.issn.1009-6663.2021.10.032. [15] 杨书玉,刘士林,张雪琴.吸烟与肺部感染在慢性阻塞性肺部疾病中的发病机理探讨[J].临床肺科杂志, 2009, 14(6): 796-797. DOI: 10.3969/j.issn.1009-6663.2009.06.043. [16] SINGH D, AGUSTI A, ANZUETO A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019[J]. Eur Respir J, 2019, 53(5): 1900164. DOI: 10.1183/13993003.00164-2019. [17] HILL A T, SULLIVAN A L, CHALMERS J D, et al. British thoracic society guideline for bronchiectasis in adults[J]. Thorax, 2019, 74(Suppl 1): 1-69. DOI: 10.1136/thoraxjnl-2018-212463. [18] POLVERINO E, GOEMINNE P C, MCDONNELL M J, et al. European Respiratory Society guidelines for the management of adult bronchiectasis[J]. Eur Respir J, 2017, 50(3): 1700629. DOI: 10.1183/13993003.00629-2017. [19] 冯明发,张薇.支气管扩张症合并慢性阻塞性肺疾病的研究进展[J].临床与病理杂志, 2021, 41(10): 2461-2467. [20] 慢性阻塞性肺疾病糖皮质激素规范管理撰写组.慢性阻塞性肺疾病糖皮质激素规范管理专家共识(2021版)[J].中华结核和呼吸杂志, 2021, 44(12): 1054-1063. DOI: 10.3760/cma.j.cn112147-20210802-00543. [21] PLEASANTS R A, WANG T S, XU X H, et al. Nebulized corticosteroids in the treatment of COPD exacerbations: systematic review, meta-analysis, and clinical perspective[J]. Respir Care, 2018, 63(10): 1302-1310. DOI: 10.4187/respcare.06384. [22] 刘智霖,史利卿,马建岭,等.慢性阻塞性肺疾病气道黏液高分泌脏腑相关病机及证治探讨[J].世界中医药, 2022, 17(9): 1316-1321. DOI: 10.3969/j.issn.1673-7202.2022.09.021. [23] 周克琴,刘炜.中医药治疗慢性阻塞性肺疾病气道黏液高分泌研究进展[J].亚太传统医药, 2021, 17(9): 201-204. [24] 中华预防医学会疫苗与免疫分会.主要慢性病人群流感疫苗和肺炎球菌疫苗接种专家共识[J].中国疫苗和免疫, 2021, 27(6): 711-742. DOI: 10.19914/j.CJVI.2021130. [25] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志, 2007, 30(1): 8-17. [26] 尹涵,李新如,张明洋,等.泛福舒治疗稳定期支气管扩张症的疗效观察[J].西部医学, 2019, 31(6): 949-952, 957. DOI: 10.3969/j.issn.1672-3511.2019.06.027. [27] 苏慧霞.细菌溶解产物对婴幼儿毛细支气管炎辅助治疗的疗效观察[J].临床肺科杂志, 2017, 22(4): 708-710. DOI: 10.3969/j.issn.1009-6663.2017.04.037. [28] 娄红超,谢汉华,卢乃棉.泛福舒对老年COPD患者的肺功能和细胞免疫力的分析[J].中华肺部疾病杂志电子版), 2021, 14(3): 315-317. DOI: 10.3877/cma.j.issn.1674-6902.2021.03.012. [29] 曾敦煌,黄杰凤,王碧瑛,等.细菌溶解产物治疗老年人慢性阻塞性肺疾病的临床疗效[J].中华老年医学杂志, 2019, 38(7): 717-721. DOI: 10.3760/cma.j.issn.0254-9026.2019.07.002. [30] 余露,臧巧英,梁蕊,等.慢性阻塞性肺部疾病康复治疗进展[J].中国康复医学杂志, 2022, 37(3): 427-431. DOI: 10.3969/j.issn.1001-1242.2022.03.026. [31] 胡相悦,范耀菊.基于指南构建肺康复运动方案对慢性阻塞性肺疾病稳定期患者运动耐力、衰弱状况和生活质量的影响研究[J].实用心脑肺血管病杂志, 2021, 29(2): 64-69.DOI: 10.12114/j.issn.1008-5971.2021.00.020. [32] 王永琴,王丽波,郑露.八段锦联合肺康复训练对稳定期COPD患者肺功能的影响[J].中国康复, 2022, 37(4): 232-235. DOI: 10.3870/zgkf.2022.04.009. [33] 宫玉翠,陈洁雅,李平东,等.慢性呼吸疾病肺康复护理专家共识[J].中华护理杂志, 2020, 55(5): 709-710. DOI: 10.3761/j.issn.0254-1769.2020.05.013. |